CU23847B1 - 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal - Google Patents

2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal

Info

Publication number
CU23847B1
CU23847B1 CU2009000225A CU20090225A CU23847B1 CU 23847 B1 CU23847 B1 CU 23847B1 CU 2009000225 A CU2009000225 A CU 2009000225A CU 20090225 A CU20090225 A CU 20090225A CU 23847 B1 CU23847 B1 CU 23847B1
Authority
CU
Cuba
Prior art keywords
treatment
useful
bencimidazoles
piperidinyl
cellular growth
Prior art date
Application number
CU2009000225A
Other languages
English (en)
Other versions
CU20090225A7 (es
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Michael John Munchhof
Lawrence Alan Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20090225A7 publication Critical patent/CU20090225A7/es
Publication of CU23847B1 publication Critical patent/CU23847B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I ESPACIO PARA LA FÓRMULA o una sal farmacéuticamente aceptable del mismo, en la que R1, R2, R3A, R3B, R4, R5, X, m y n son como se definen en el presente documento. Tales derivados de bencimidazol novedosos son útiles en el tratamiento de crecimiento celular anormal, tal como cáncer, en mamíferos. La presente invención también se refiere a un procedimiento de uso de tales compuestos en el tratamiento de crecimiento celular anormal en mamíferos, especialmente seres humanos y a composiciones farmacéuticas que contienen tales compuestos.
CU2009000225A 2007-06-29 2009-12-21 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal CU23847B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (en) 2007-06-29 2008-06-16 Benzimidazole derivatives

Publications (2)

Publication Number Publication Date
CU20090225A7 CU20090225A7 (es) 2012-02-15
CU23847B1 true CU23847B1 (es) 2012-10-15

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000225A CU23847B1 (es) 2007-06-29 2009-12-21 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal

Country Status (46)

Country Link
US (2) US8148401B2 (es)
EP (1) EP2170860B9 (es)
JP (2) JP4567099B2 (es)
KR (1) KR101143246B1 (es)
CN (1) CN101687841B (es)
AP (1) AP2377A (es)
AR (1) AR067346A1 (es)
AU (1) AU2008272641B2 (es)
BR (1) BRPI0813412B8 (es)
CA (1) CA2690953C (es)
CL (1) CL2008001922A1 (es)
CO (1) CO6160232A2 (es)
CR (1) CR11150A (es)
CU (1) CU23847B1 (es)
CY (2) CY1118650T1 (es)
DK (1) DK2170860T5 (es)
DO (1) DOP2009000278A (es)
EA (1) EA016888B1 (es)
EC (1) ECSP099803A (es)
ES (1) ES2609258T3 (es)
FR (1) FR20C1038I2 (es)
GE (1) GEP20125702B (es)
GT (1) GT200900328A (es)
HK (1) HK1139658A1 (es)
HN (1) HN2008000974A (es)
HR (1) HRP20161562T2 (es)
HU (2) HUE030052T4 (es)
IL (1) IL202420A (es)
LT (2) LT2170860T (es)
MA (1) MA31466B1 (es)
ME (1) ME00962B (es)
MY (1) MY148636A (es)
NI (1) NI200900219A (es)
NL (1) NL301057I2 (es)
NO (1) NO2020027I1 (es)
NZ (1) NZ581889A (es)
PA (1) PA8785401A1 (es)
PE (2) PE20121010A1 (es)
PL (1) PL2170860T3 (es)
PT (1) PT2170860T (es)
RS (1) RS55395B9 (es)
SI (1) SI2170860T1 (es)
TN (1) TN2009000544A1 (es)
TW (1) TWI371451B (es)
UY (1) UY31164A1 (es)
WO (1) WO2009004427A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148636A (en) 2007-06-29 2013-05-15 Pfizer Benzimidazole derivatives
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
CA2765114A1 (en) * 2009-06-11 2010-12-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
MX2012002419A (es) 2009-08-26 2012-04-19 Takeda Pharmaceutical Derivado de anillo heterociclico fusionado y uso del mismo.
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Nttドコモ ホーム基地局及びハンドオーバ方法
AU2012223509B2 (en) 2011-02-28 2016-11-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012122370A2 (en) * 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
AU2012314943B9 (en) * 2011-09-26 2017-06-08 Merck Patent Gmbh Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
IN2014DN11205A (es) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
JP6503338B2 (ja) 2013-03-15 2019-04-17 バイオマリン ファーマシューティカル インコーポレイテッド Hdac阻害剤
WO2014170350A1 (en) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ, インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
CA2983387C (en) 2015-04-24 2022-08-16 Pfizer Inc. Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2020164722A (ja) * 2019-03-29 2020-10-08 デクセリアルズ株式会社 接着剤組成物
HRP20240302T1 (hr) 2020-01-28 2024-05-10 Assia Chemical Industries Ltd Postupci za pripremu glasdegiba i njegove soli i krutih oblika glasdegib maleata i postupak za njihovu pripremu
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (en) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1638765A (zh) 2001-07-27 2005-07-13 柯里斯公司 Hedgehog信号转导途径介质、其相关组合物以及应用
DE60207894T2 (de) * 2001-12-04 2006-07-20 Actelion Pharmaceuticals Ltd. 4-(piperidyl- und pyrrolidyl-alkyl-ureido)-chinoline als urotensin ii rezeptor antagonisten
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
WO2005042495A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
CA2543918A1 (en) 2003-10-28 2005-05-12 Dean Wilson Benzimidazoles useful as modulators of ion channels
EP1807074B1 (en) * 2004-11-03 2013-10-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2008064830A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
MY148636A (en) * 2007-06-29 2013-05-15 Pfizer Benzimidazole derivatives
EP2303275A4 (en) 2008-06-17 2012-05-09 Univ Duke STANDARD RECEPTOR MODULATORS
KR101354763B1 (ko) 2008-08-25 2014-01-22 아이알엠 엘엘씨 헷지호그 경로 조절제

Also Published As

Publication number Publication date
HRP20161562T1 (hr) 2016-12-30
JP4567099B2 (ja) 2010-10-20
CY2020028I2 (el) 2020-11-25
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
CN101687841B (zh) 2013-07-10
HK1139658A1 (en) 2010-09-24
AP2009005089A0 (en) 2009-12-31
NL301057I1 (nl) 2020-07-22
US8431597B2 (en) 2013-04-30
NO2020027I1 (no) 2020-08-11
CA2690953C (en) 2012-10-02
CN101687841A (zh) 2010-03-31
PL2170860T3 (pl) 2017-05-31
CR11150A (es) 2010-02-08
PT2170860T (pt) 2017-01-04
CO6160232A2 (es) 2010-05-20
CY2020028I1 (el) 2020-11-25
ES2609258T3 (es) 2017-04-19
US20120157495A1 (en) 2012-06-21
ECSP099803A (es) 2010-01-29
DK2170860T5 (en) 2017-03-20
LTPA2020528I1 (lt) 2020-09-25
PA8785401A1 (es) 2009-01-23
HUS2000031I1 (hu) 2020-09-28
TW200911792A (en) 2009-03-16
AR067346A1 (es) 2009-10-07
GT200900328A (es) 2011-08-29
GEP20125702B (en) 2012-12-10
HN2008000974A (es) 2011-01-24
BRPI0813412A2 (pt) 2014-12-30
BRPI0813412B8 (pt) 2021-05-25
WO2009004427A3 (en) 2009-06-04
EP2170860A2 (en) 2010-04-07
SI2170860T1 (sl) 2017-01-31
MA31466B1 (fr) 2010-06-01
PE20121010A1 (es) 2012-08-06
BRPI0813412B1 (pt) 2020-01-21
CL2008001922A1 (es) 2009-01-02
AU2008272641A1 (en) 2009-01-08
LTC2170860I2 (lt) 2022-03-10
IL202420A0 (en) 2010-06-30
NL301057I2 (nl) 2020-09-10
RS55395B1 (sr) 2017-04-28
DK2170860T3 (en) 2017-01-09
EA200971104A1 (ru) 2010-06-30
EA016888B1 (ru) 2012-08-30
FR20C1038I1 (es) 2020-10-02
NZ581889A (en) 2011-05-27
HRP20161562T2 (hr) 2017-04-21
WO2009004427A2 (en) 2009-01-08
EP2170860B1 (en) 2016-11-02
MY148636A (en) 2013-05-15
EP2170860B9 (en) 2017-02-22
FR20C1038I2 (fr) 2021-08-13
DOP2009000278A (es) 2009-12-31
AU2008272641B2 (en) 2013-08-29
KR20100028120A (ko) 2010-03-11
LT2170860T (lt) 2017-01-10
AP2377A (en) 2012-03-07
JP2010531869A (ja) 2010-09-30
KR101143246B1 (ko) 2012-05-18
CA2690953A1 (en) 2009-01-08
UY31164A1 (es) 2009-01-30
IL202420A (en) 2014-05-28
CY1118650T1 (el) 2017-07-12
TN2009000544A1 (fr) 2011-03-31
CU20090225A7 (es) 2012-02-15
HUE030052T2 (hu) 2017-04-28
JP2010280693A (ja) 2010-12-16
TWI371451B (en) 2012-09-01
RS55395B9 (sr) 2020-01-31
US20090005416A1 (en) 2009-01-01
ME00962B (me) 2012-06-20
HUE030052T4 (en) 2017-06-28
US8148401B2 (en) 2012-04-03

Similar Documents

Publication Publication Date Title
CU23847B1 (es) 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CU23813A3 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
ECSP10010346A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR20120296A (es) Nuevos compuestos de espiropiperidina
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
UY31141A1 (es) Compuestos de piperidina y sus usos
ECSP11010816A (es) Nuevos Compuestos
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CR10199A (es) Derivados de benzimidazol
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
CU20080126A7 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UA93313C2 (en) Benzimidazole derivatives
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
NI200500205A (es) "derivados de pirimidina para el tratamiento del crecimiento celular anorma."
CU20080204A7 (es) Derivados de triazolopirazina

Legal Events

Date Code Title Description
FG Grant of patent